Company: SHPH
Filing Date: 2025-03-19
Form Type: PRE 14A
Source: 0001493152-25-010886
Chunk: 8

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-19
Form: PRE 14A
Chunk 8
---
 Directors in the same manner it considers nominees from other sources. Our Board of Directors retains the ultimate authority to nominate a candidate for election by the stockholders as a director or to fill any vacancy that may occur. In identifying prospective director candidates, the Nominating and Corporate Governance Committee may consider all facts and circumstances that it deems appropriate or advisable, including, among other things, the skills of the prospective director candidate, his or her depth and breadth of business experience or other background characteristics, his or her independence and the needs of the Board of Directors. In addition, the Nominating and Corporate Governance Committee will consider diversity of background including diversity of race, ethnicity, international background, gender and age when evaluating candidates for board membership. All members of the Nominating and Corporate Governance Committee are independent directors. A copy of our Nominating and Corporate Governance Committee Charter is located under the “Investor Relations-Governance” tab on our website at www.shuttlepharma.com.

Audit Committee

| MEMBERS                    |     | MEETINGS               
 HELD IN 2024: 5*       
 ACTIONS                
 BY WRITTEN CONSENT: 2* |
| Steve                      
 Richards, MBA, CPA (Chair) |     |                        |
| George                     
 Scorsis                    |     |                        |
| Oleh                       
 Nabyt                      |     |                        |

The Audit Committee of our Board of Directors is our standing audit committee established in accordance with Section 3(a)(58)(A) of the Exchange Act.

* Messrs. Scorsis and Nabyt joined as the Company’s Board in February 2025. Accordingly, our previous Audit Committee members participated in the Audit Committee meetings held in 2024, or took action by written consent in 2024, until their resignations in February 2025.

| 8 |

KEY RESPONSIBILITIES

| ● | Reviews                                                                                                                               
 and discusses the financial statements for the financial year ended.                                                                  |
|:--|:--------------------------------------------------------------------------------------------------------------------------------------|
| ● | Oversees                                                                                                                              
 the accounting and financial reporting processes of the Company and the audits of the financial statements of the Company.            |
| ● | Discusses                                                                                                                             
 with the Company’s independent accountants the matters required to be discussed by the statement on Auditing Standards No.            
 61, as amended.                                                                                                                       |
| ● | Reviews                                                                                                                               
 written disclosures and letters from the independent accountant required by applicable requirements of the Public Company Accounting  
 Oversight Board, or the PCAOB, regarding